STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

NCT01653067 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Rituximab, Temsirolimus, DHAP, intravenous

Sponsor

Mathias Witzens-Harig

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]